Download MendeleyDARPin-induced reactivation of p53 in HPV-positive cells.
Munick, P., Strubel, A., Balourdas, D.I., Funk, J.S., Mernberger, M., Osterburg, C., Dreier, B., Schaefer, J.V., Tuppi, M., Yuksel, B., Schafer, B., Knapp, S., Pluckthun, A., Stiewe, T., Joerger, A.C., Dotsch, V.(2025) Nat Struct Mol Biol 32: 790-801
- PubMed: 39789211
- DOI: https://doi.org/10.1038/s41594-024-01456-7
- Primary Citation of Related Structures:
8RCI, 9FZB - PubMed Abstract:
Infection of cells with high-risk strains of the human papillomavirus (HPV) causes cancer in various types of epithelial tissue. HPV infections are responsible for ~4.5% of all cancers worldwide. Tumorigenesis is based on the inactivation of key cellular control mechanisms by the viral proteins E6 and E7. The HPV E6 protein interacts with the cellular E3 ligase E6AP, and this complex binds to the p53 DNA-binding domain, which results in degradation of p53. Inhibition of this interaction has the potential to reactivate p53, thus preventing oncogenic transformation. Here we describe the characterization of a designed ankyrin repeat protein that binds to the same site as the HPV E6 protein, thereby displacing the E3 ligase and stabilizing p53. Interaction with the designed ankyrin repeat protein does not affect p53 DNA binding or the crucial MDM2 negative feedback loop but reactivates a p53-dependent transcriptional program in HeLa (HPV18-positive) and SiHa (HPV16-positive) cells, suggesting a potential therapeutic use.
- Institute of Biophysical Chemistry and Center for Biomolecular Magnetic Resonance, Goethe University, Frankfurt, Germany.
Organizational Affiliation:
